• Baijian Gu, Zhe Yu, Chong Shi, Chengqiu Yan, Bixin Chen, and Jianhua Zhou.
• Changchun University of Chinese Medicine, Changchun City, Jilin Province, China,Urology, First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun City, Jilin Province, China,Proctology, First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun City, Jilin Province, China,Electronic data processing management science, Health Information Center of Jilin Province, Changchun City, Jilin, China.
• Medicine (Baltimore). 2022 Mar 18; 101 (11).

BackgroundInflammatory bowel disease (IBD) is a chronic disease whose etiology is not yet fully understood, and their course is characterized by periods of exacerbation and remission. In quite a few cases, actual disease remission may also accompany with inflammatory bowel disease (IBS)-like symptoms such as abdominal pain, bloating, flatulence, and diarrhea, may greatly impact quality of life. An army of strong evidence to support the FODMAPs diet (LFD) compounds as an effective dietary approach to IBS treatment. However, there is no significant evidence showing the effectiveness of LFD in treating quiescent IBD and its side effects; this lack of evidence is also an important factor hindering its promotion in the treatment of IBD and its complications. Therefore, this systematic review and meta-analysis will evaluate the efficacy and safety of LFD in the treatment of quiescent IBD patients with IBS-like symptoms.MethodWe searched the following databases from their establishment until December 2021: PubMed, Web of Science, Embase, Cochrane Library, CNKI, VIP, and Wanfang databases. No restrictions regarding publication date or language were applied. Keywords such as "Crohn's disease," "ulcerative colitis," "inflammatory bowel disease," and "FODMAPs" have been combined for search. Ongoing and unpublished research in the Clinical Trials Registry Research will also be included. At the same time, we will manually search all reference lists from relevant systematic reviews for other eligible studies. The selected studies were randomized controlled clinical trials. We will meta-analyze the selected literature by Review Manager software (REVMAN v5.4 Cochrane Collaboration). Two researchers will independently review the research selection, data extraction, and research quality assessments. Finally, we will observe the outcome measures.ResultsThis study will provide evidence-based data for TFD treatment of IBD and provide new treatment options for future clinical applications.Ethics And DisseminationThe protocol of the systematic review does not require ethical approval because it does not involve humans. This article will be published in peer-reviewed journals and presented at relevant conferences.Registration NumberINPLASY202220060.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

28 keywords...

hide…